[go: up one dir, main page]

AU2022369036A1 - A synthesis scheme and procedures for preparing a sik3 inhibitor and intermediates thereof - Google Patents

A synthesis scheme and procedures for preparing a sik3 inhibitor and intermediates thereof Download PDF

Info

Publication number
AU2022369036A1
AU2022369036A1 AU2022369036A AU2022369036A AU2022369036A1 AU 2022369036 A1 AU2022369036 A1 AU 2022369036A1 AU 2022369036 A AU2022369036 A AU 2022369036A AU 2022369036 A AU2022369036 A AU 2022369036A AU 2022369036 A1 AU2022369036 A1 AU 2022369036A1
Authority
AU
Australia
Prior art keywords
compound
equiv
preparing
formula
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022369036A
Other languages
English (en)
Inventor
Tommaso CANELLI
Lorenzo CARUANA
Stefania MANGIOLA
Giuseppe MARSEGLIA
WenKe WANG
Xianglin ZHAO
Ziqiang ZHAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IOmx Therapeutics AG
Original Assignee
IOmx Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IOmx Therapeutics AG filed Critical IOmx Therapeutics AG
Publication of AU2022369036A1 publication Critical patent/AU2022369036A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/36Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AU2022369036A 2021-10-19 2022-10-19 A synthesis scheme and procedures for preparing a sik3 inhibitor and intermediates thereof Pending AU2022369036A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21203530 2021-10-19
EP21203530.7 2021-10-19
PCT/EP2022/079131 WO2023067021A1 (fr) 2021-10-19 2022-10-19 Schéma de synthèse et procédures de préparation d'un inhibiteur de sik3 et d'intermédiaires de celui-ci

Publications (1)

Publication Number Publication Date
AU2022369036A1 true AU2022369036A1 (en) 2024-05-02

Family

ID=79231044

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022369036A Pending AU2022369036A1 (en) 2021-10-19 2022-10-19 A synthesis scheme and procedures for preparing a sik3 inhibitor and intermediates thereof

Country Status (10)

Country Link
US (1) US20250296928A1 (fr)
EP (1) EP4419521A1 (fr)
JP (1) JP2024539268A (fr)
KR (1) KR20240115232A (fr)
CN (1) CN118369321A (fr)
AU (1) AU2022369036A1 (fr)
CA (1) CA3234823A1 (fr)
IL (1) IL312288A (fr)
MX (1) MX2024004690A (fr)
WO (1) WO2023067021A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3643713B1 (fr) 2018-10-23 2025-07-30 iOmx Therapeutics AG Inhibiteurs de kinase hétérocycliques et leurs utilisations
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
EP4643861A1 (fr) 2024-04-30 2025-11-05 iOmx Therapeutics AG Inhibiteur de kinase heteroaryle halogenee destine au traitement du sarcome des tissus mous et des tumeurs vasculaires
WO2025229127A1 (fr) 2024-04-30 2025-11-06 Iomx Therapeutics Ag Inhibiteur de kinase hétéroaryle halogéné pour le traitement d'un sarcome de tissu mou et de tumeurs vasculaires

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101812060B (zh) * 2010-02-02 2011-08-17 南京卡文迪许生物工程技术有限公司 一种简捷制备高纯度达沙替尼的新方法以及中间体化合物
AU2015300782B2 (en) 2014-08-08 2020-04-16 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (SIK) inhibitors
CN111163771B (zh) 2017-02-28 2023-07-14 通用医疗公司 嘧啶并嘧啶酮类作为sik抑制剂的用途
DK3391907T3 (da) 2017-04-20 2020-03-09 Iomx Therapeutics Ag Intracellulær kinase sik3, der er associeret med resistens over for antitumorimmunresponser, og anvendelser deraf
EP3643713B1 (fr) * 2018-10-23 2025-07-30 iOmx Therapeutics AG Inhibiteurs de kinase hétérocycliques et leurs utilisations
EP3901151A1 (fr) * 2020-04-21 2021-10-27 iOmx Therapeutics AG Hétéroaryle halogéné et autres inhibiteurs de kinase hétérocycliques et leurs utilisations
WO2021219731A2 (fr) * 2020-04-28 2021-11-04 Iomx Therapeutics Ag Inhibiteurs de kinase bicycliques et leurs utilisations

Also Published As

Publication number Publication date
CA3234823A1 (fr) 2023-04-27
WO2023067021A1 (fr) 2023-04-27
EP4419521A1 (fr) 2024-08-28
CN118369321A (zh) 2024-07-19
KR20240115232A (ko) 2024-07-25
US20250296928A1 (en) 2025-09-25
IL312288A (en) 2024-06-01
JP2024539268A (ja) 2024-10-28
MX2024004690A (es) 2024-07-10

Similar Documents

Publication Publication Date Title
AU2022369036A1 (en) A synthesis scheme and procedures for preparing a sik3 inhibitor and intermediates thereof
ES2855135T3 (es) Amidas heterocíclicas como inhibidores de quinasa
EP3177612B1 (fr) Derives de pyrimidine eventuellement condensee utiles dans le traitement de maladies inflammatoires, metaboliques, oncologiques et auto-immunes
AU2020203464A1 (en) Sulfonylureas and related compounds and use of same
ES2856125T3 (es) Derivado de sulfonamida y composición farmacéutica que contiene la misma
CN101657453B (zh) 作为PKC-θ抑制剂的嘌呤类
AU2014234105A1 (en) Sodium channel modulators for the treatment of pain
CN101677554A (zh) 化合物
JP6704422B2 (ja) キナゾリン誘導体の塩およびその製造方法
EP3159341B1 (fr) Analogue de pyridino [1,2-a]pyrimidone utilisé en tant qu'inhibiteur de pi3k
KR20130046436A (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도
Kim et al. Discovery of an orally bioavailable gonadotropin-releasing hormone receptor antagonist
JP5324785B2 (ja) 複素環アミド化合物及びその用途
EP4129402A1 (fr) Dérivé d'hydroxypyrrolidine et son application médicinale
EP4532011A1 (fr) Nouveaux dérivés pour le traitement de troubles médiés par trpm3
CZ20023773A3 (cs) Amidy (R)-enantiomerů 2-arylpropionových kyselin, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
WO2014062204A1 (fr) Inhibiteurs de métalloprotéinases matricielles et méthodes de traitement de la douleur et d'autres maladies
WO2025218831A2 (fr) Dérivé de thiadiazolidinone ayant une activité inhibitrice de ptpn2/ptpn1, son procédé de préparation et son utilisation
AU2023276867A1 (en) New derivatives for treating trpm3 mediated disorders
EP4499636A2 (fr) Dérivés de pyrazolo[1,5-a]pyridine pour le traitement de troubles médiés par trpm3
BR112018015855B1 (pt) Derivado de sulfonamida
HK1236034B (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
SK12142002A3 (sk) Substituované 8,8a-dihydro-3aH-indeno[1,2-d]tiazoly, spôsob ich prípravy a ich použitie ako liečiv